Refractory generalized seizures as a possible side effect of bevacizumab in a colon cancer patient.
Med Oncol
; 29(2): 1017-9, 2012 Jun.
Article
in En
| MEDLINE
| ID: mdl-21461780
ABSTRACT
Bevacizumab, which is a humanized monoclonal antibody against vascular endothelial growth factor, is used to treat metastatic cancers of the colon. Adverse effects common with bevacizumab treatment are hypertension, arterial-venous thrombosis, bleeding, gastrointestinal perforation, and proteinuria. To date, there have been no reports of refractory seizure following treatment with bevacizumab. We describe a patient who presented with refractory generalized tonic-clonic seizures after receiving last dose of bevacizumab for treatment of metastatic colorectal cancer with FOLFIRI and bevacizumab regimen.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Seizures
/
Colonic Neoplasms
/
Angiogenesis Inhibitors
/
Antibodies, Monoclonal, Humanized
/
Liver Neoplasms
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Med Oncol
Journal subject:
NEOPLASIAS
Year:
2012
Document type:
Article
Affiliation country:
Turkey